An 80 year old woman complains of 3 months of rash on her back. It is modestly pruritic. The lesions are both annular and papular appearing over her back, torso and upper arms. She also complains of pain and swelling in her fingers.

Lancet today published the results of the phase 3, prospecitive, multinational, double-blind, randomized controlled trial of secukinumab (an anti-IL-17A monoclonal antibody) in active psoriatic arthritis.

Currently there are no FDA-approved medications for the treatment of digital ulcerations in the United States.  Digital ulcers are a common, unfortunate and difficult to manage consequence of the vascular obliteration and fibrosis that accompanies systemic sclerosis.

Estimates on the prevalence of psoriatic arthritis among psoriasis patients has varied widely, ranging from 5-40%.  A systematic review of the literature shows that prevalence of undiagnosed PsA was 15.5% when all studies were considered and 10.1% when only epidemiological studies were consi

A 12-week, phase III, non-inferiority, randomized clinical trial of tofacitinib, etanercept or placebo was conducted in 1106 patients with plaque psoriasis.

A prospective study of sildenafil was conducted in 25 centers that included 83 patients and 192 digital ulcers at entry. The odds of healing ulcers was less, but not significant, for sildenafil.

The FDA has granted adalimumab (Humira) orphan drug designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (HS) (Hurley Stage II and Hurley Stage III disease).